✦ LIBER ✦

Cost-effectiveness of donepezil 23 mg in the treatment of moderate to severe Alzheimer's disease from a US payor perspective

✍ Scribed by Knoth, Russell; Bentley, Tanya; Richardson, Sharon; Ramos, Harry

Book ID: 123077395
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 52 KB
Volume: 7
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2011.05.2297

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Analyzing the impact of 23 mg/day donepe

Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease

✍ Steven H Ferris, Frederick A Schmitt, Judith Saxton… 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 334 KB

Long-term safety and tolerability of don

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease

✍ Pierre Tariot, Steven Salloway, Jane Yardley, Joan Mackell, Margaret Moline 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 197 KB

Effects of donepezil 23 mg on Severe Imp

Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer’s disease: evaluating the impact of baseline severity

✍ Ferris, Steven; Cummings, Jeffrey; Christensen, Daniel; Doody, Rachelle; Farlow, 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 286 KB

Subgroup Analysis of US and Non-US Patie

Subgroup Analysis of US and Non-US Patients in a Global Study of High-Dose Donepezil (23 mg) in Moderate and Severe Alzheimer's Disease

✍ Salloway, S.; Mintzer, J.; Cummings, J. L.; Geldmacher, D.; Sun, Y.; Yardley, J. 📂 Article 📅 2012 🏛 SAGE Publications 🌐 English ⚖ 534 KB

Evaluating the cognitive effects of done

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response

✍ Marwan Sabbagh, Jeffrey Cummings, Daniel Christensen, Rachelle Doody… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 347 KB

Tolerability of switching from donepezil

Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease

✍ Gunhild Waldemar; Maritta Hyvärinen; Mette Krog Josiassen; Alex Kørner; Heikki L 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB 👁 2 views

This study investigates the tolerability, safety and efficacy of abrupt or stepwise switching from donepezil to memantine treatment in patients with moderate-to-severe Alzheimer's disease (AD). Outpatients (Table 1), !50 years, with dementia of the Alzheimer's type (DSM-IV-TR), MMSE 18 and receiving